Chris Klomp discusses Trump’s MFN drug pricing goals, TrumpRx

Tara Bannow covers hospitals, providers, and insurers. You can reach Tara on Signal at tarabannow.70.

Chris Klomp, a leading figure in the federal health department, provided a critical analysis of President Trump’s drug discount initiative, TrumpRx, during a presentation at a STAT event on Thursday. 

While Trump has hailed the platform as “transformative” and claimed it would bring about the “largest reduction in prescription drug prices in history,” Klomp presented a more tempered view at STAT’s Breakthrough Summit East in New York. He clarified that the initiative was not designed for the majority of Americans who have health insurance and dismissed the notion that Trump’s drug policies equate to price controls. 

Klomp stated, “The goal was not actually some massive reach,” noting that around 170 million Americans have commercial insurance, 68 million are covered by Medicare, and the remainder are mostly on Medicaid and CHIP. He emphasized that TrumpRx is primarily aimed at those paying with cash.